UroGen Pharma (URGN) PT Raised to $40 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts URGN Hot Sheet
Price: $32.72 -2.27%
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Oppenheimer analyst Leland Gershell raised the price target on UroGen Pharma (NASDAQ: URGN) to $40.00 (from $34.00) while maintaining a Outperform rating.
You May Also Be Interested In
- UroGen's Jelmyto shows durable response in 5-year cancer study
- Norwegian Cruise (NCLH) PT Raised to $22 at Freedom Broker, Upgrades to Buy
- Intel (INTC) PT Lowered to $90 at Piper Sandler
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
